Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.

Authors: Mo, Fengzhen; Duan, Siliang; Jiang, Xiaobing; Yang, Xiaomei; Hou, Xiaoqiong; Shi, Wei; Carlos, Cueva Jumbo Juan; Liu, Aiqun; Yin, Shihua; Wang, Wu; Yao, Hua; Yu, Zihang; Tang, Zhuoran; Xie, Shenxia; Ding, Ziqiang; Zhao, Xinyue; Hammock, Bruce D; Lu, Xiaoling

Published In Signal Transduct Target Ther, (2021 02 25)

Abstract: Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment of hematological malignant tumors; however, its efficacy towards solid cancer remains challenging. We therefore focused on developing nanobody-based CAR-T cells that treat the solid tumor. CD105 expression is upregulated on neoangiogenic endothelial and cancer cells. CD105 has been developed as a drug target. Here we show the generation of a CD105-specific nanobody, an anti-human CD105 CAR-T cells, by inserting the sequences for anti-CD105 nanobody-linked standard cassette genes into AAVS1 site using CRISPR/Cas9 technology. Co-culture with CD105+ target cells led to the activation of anti-CD105 CAR-T cells that displayed the typically activated cytotoxic T-cell characters, ability to proliferate, the production of pro-inflammatory cytokines, and the specific killing efficacy against CD105+ target cells in vitro. The in vivo treatment with anti-CD105 CAR-T cells significantly inhibited the growth of implanted CD105+ tumors, reduced tumor weight, and prolonged the survival time of tumor-bearing NOD/SCID mice. Nanobody-based CAR-T cells can therefore function as an antitumor agent in human tumor xenograft models. Our findings determined that the strategy of nanobody-based CAR-T cells engineered by CRISPR/Cas9 system has a certain potential to treat solid tumor through targeting CD105 antigen.

PubMed ID: 33627635 Exiting the NIEHS site

MeSH Terms: Animals; CRISPR-Cas Systems/genetics; Cell Line, Tumor; Endoglin/immunology*; Endoglin/therapeutic use; Humans; Immunotherapy*; Immunotherapy, Adoptive/methods; Male; Mice; Neoplasms/immunology; Neoplasms/therapy*; Receptors, Antigen, T-Cell/genetics; Receptors, Antigen, T-Cell/immunology; Receptors, Chimeric Antigen/genetics; Receptors, Chimeric Antigen/immunology*; Single-Domain Antibodies/immunology; Single-Domain Antibodies/pharmacology; T-Lymphocytes, Cytotoxic/immunology; Xenograft Model Antitumor Assays

Back
to Top